Overview

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.